For healthcare professionals. Reglory products are medical devices for use by trained practitioners only.
REGLORYEurope

Reglory/The range/EYES BLACK

Polynucleotide

Reglory
EYES BLACK

Awaken your skin's natural radiance.

€35

VAT and European delivery included

1 x 2 ml syringe

For trained practitioners, clinics and authorised distributors. Confirmation is required at checkout.

Reglory EYES BLACK packaging

What it is

Reglory EYES BLACK

Reglory Eyes Black is a premium eye-area rejuvenation booster infused with 1% high-purity polynucleotides. Designed for the delicate under-eye area, it targets dark circles, fine lines, enlarged pores and skin laxity.

A single active, at ten times the polynucleotide load per syringe of the standard Eyes formula, with a published point-by-point protocol.

Composition

Polynucleotide
20 mg / 2 ml — PN 1%

Awaken your skin's natural radiance.

How it works

Three things it does first

Brightens skin tone

Firms and tightens skin

The full list of effects, the areas of application and the protocol are below. All of it is reproduced from the manufacturer's catalogue for this product.

Benefits & effects

What it addresses

  • Brightens skin tone
  • Firms and tightens skin
  • Reduces dark circles and pores
  • Smooths fine lines and wrinkles
  • Supports scar recovery

Areas of application: Around the eyes · Face · Neck · Back of hands

Presentation & protocol

Presentation
1 × 2 ml pre-filled syringe
Indication
Upper dermis
Injection depth
Periorbital area approx. 0.5 mm; other facial areas 0.8–1.15 mm
Volume per point
Approximately 0.15 cc; 6 points per side, 1 ml per side
Needle
30–32G. Needles are not included
Coverage
One 2 ml syringe covers the eye area or the full face
Treatment interval
2–3 sessions per month, 1 week apart
Duration
Up to 6 months
Shelf life
36 months from the date of manufacture
Storage
Cool, dry place, 1–30 °C

Method

How it is used

1   Disinfect
Thoroughly disinfect the treatment area before the procedure.
2   Anaesthetise
Apply topical anaesthesia if necessary.
3   Prepare
Insert a 30–32G needle into the syringe. Needles are not included.
4   Inject
Inject approximately 0.15 cc at 6 points per side; one syringe delivers 1 ml per side.

Safe use

Seven instructions

Inspect
the product and packaging for any damage or deformation.
Check
the syringe content and dosage after opening the package.
Select
a sterile needle suitable for the injection site and connect it properly.
Avoid
injection into blood vessels to prevent tissue necrosis.
Massage
the injection site gently during and after the procedure.
Explain
all indications, contraindications and side effects to the patient beforehand.
Use
only by trained medical professionals familiar with injection techniques.

Before, after, and who it is not for

Guidance & contraindications

Before the treatment

  • No chemical peels or strong cosmetics for several days before the treatment.
  • No alcohol for at least 48 hours before the treatment.
  • No excessive heat exposure — solarium, sauna or direct sun.

After the treatment

  • No sun or heat for 4 days; use SPF 50.
  • No intense exercise, sauna, swimming pool or crowded places for 7 days.
  • No peels or strong cosmetics for several days.
  • No alcohol for 24 hours and no make-up for 48 hours.
  • Strict hygiene — single-use towels, clean brushes, fresh bed linen.

Possible side effects

  • Mild swelling at the injection site
  • Slight redness and minor injection marks
  • Mild bruising
  • Erythema, itching or irritation
  • Possible allergic reactions to the products used in the treatment

Contraindications

  • Under 18 years of age
  • Pregnancy or breastfeeding
  • Allergy to the product ingredients or to hyaluronic acid
  • Skin infection — bacterial, fungal or viral — inflammation or active herpes
  • Severe acne requiring medical treatment
  • Coagulation disorders or anticoagulant therapy
  • High allergic susceptibility, skin allergies, irritated or damaged skin
  • Connective tissue disease, hypertrophic scarring or keloid tendency
  • Autoimmune disease, cancer, or ongoing chemotherapy or radiotherapy
  • Immunosuppressants, corticosteroids in the last 6–8 weeks, or retinoids in the last 6 months
  • Recent surgery (2 months) or cryotherapy (6 months)
  • Multiple naevi, extensive telangiectasia or psoriasis
  • Severe psychiatric disorders affecting cooperation with the treatment

Treatment protocols may vary depending on the practitioner's clinical experience and treatment environment. This material is provided as a guideline to support safe and effective procedures. This product should only be used by trained professionals or doctors.

We use only the cookies required for the site to work. Analytics and marketing cookies are set only with your consent. Cookie policy.